Department of Hepatobiliary Surgery, SouthWestern Hospital, Chongqing, China.
Transfus Med Rev. 2012 Apr;26(2):129-41. doi: 10.1016/j.tmrv.2011.09.002. Epub 2011 Oct 19.
This article provides an overview of the current knowledge relating to the potential use of bone marrow-derived mesenchymal stem cells (BM-MSCs) acting as immunosuppressants after liver transplantation. Clinical use of BM-MSCs in liver transplantation remains experimental, as there is uncertainty as to their mechanism of action, conflicting studies in animal models, and the possibility of their cellular fusion with hepatocytes leading to potentially genetically unstable hepatocytes. These obstacles, to their underuse, have been decreasing, and BM-MSCs have elicited great interest for possible use in solid organ transplantation. Bone marrow-derived-MSCs, when transplanted systemically, might positively influence grafted organ outcome through cell-cell contact or the secretion of soluble factors that are immunomodulatory. Thus, the use of BM-MSCs to modulate organ rejection may directly or indirectly influence the survival properties of transplanted livers.
本文概述了骨髓间充质干细胞（BM-MSCs）在肝移植后作为免疫抑制剂的潜在用途的现有知识。BM-MSCs 在肝移植中的临床应用仍然是实验性的，因为其作用机制不确定，动物模型中的研究结果相互矛盾，以及它们与肝细胞融合的可能性导致潜在的遗传不稳定的肝细胞。这些阻碍其应用的因素正在减少，BM-MSCs 因其可能在实体器官移植中的应用而引起了极大的兴趣。骨髓来源的间充质干细胞通过细胞-细胞接触或分泌免疫调节的可溶性因子，系统移植可能会对移植物的结果产生积极影响。因此，使用 BM-MSCs 来调节器官排斥可能直接或间接地影响移植肝脏的存活特性。
